Epitope-targeted anthrax vaccine
AssigneeThe Regents of the University of Michigan
InventorsKemp B. Cease, Jon Oscherwitz
Life of this patent
Estimating the term…
Abstract
Anthrax vaccine compositions comprise a segment of a PA toxin protein that stimulates a B cell immune response specific for a defined epitope on the protective antigen of B. anthracis, a pharmaceutical excipient and optionally, one or more other protein segments comprising epitopes that augment the B cell response by stimulating a T cell immune response. The pharmaceutical compositions are useful for vaccinating individuals so as to confer protection from disease caused by B. anthracis including anthrax disease resulting from anthrax spore inhalation.
Claims36
An immunogen comprising:
- a loop neutralizing determinant peptide, the peptide comprising amino acids 304-319 or amino acids 305-319 of Bacillus anthracis protective antigen or a functional variant thereof;
- and
- a helper T-cell epitope coupled to the peptide.
An immunogen comprising a multiple antigenic peptide comprising a plurality of segments, each segment comprising a loop neutralizing determinant peptide comprising amino acids 304-319 or amino acids 305-319 of Bacillus anthracis protective antigen or a functional variant thereof.
Dependencies are inferred from the claim text.